Auris Medical (EARS) Getting Somewhat Positive Media Coverage, Accern Reports
Media headlines about Auris Medical (NASDAQ:EARS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Auris Medical earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.5857002044789 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Contrasting Auris Medical (EARS) & The Competition (americanbankingnews.com)
- Only the Technical Indicators on Auris Medical Holding AG (EARS) – Wall Street Morning (wallstreetmorning.com)
- Another motive To buy these stock: NVIDIA Corporation, (NASDAQ: NVDA), Auris Medical Holding AG, (NASDAQ … – Stocks In The News (press release) (tradingnewsnow.com)
- Who Really Owns Auris Medical Holding AG (EARS)? (finance.yahoo.com)
Auris Medical (EARS) traded down $0.02 during trading hours on Friday, reaching $0.44. The company’s stock had a trading volume of 477,600 shares, compared to its average volume of 489,104. The company has a debt-to-equity ratio of -14.04, a current ratio of 1.86 and a quick ratio of 1.86. Auris Medical has a 1 year low of $0.38 and a 1 year high of $1.39.
About Auris Medical
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.